ArticleJournal of immunology research2025
Detection of Monocyte Subsets in the Bone Marrow of Patients With Acute Myeloid Leukemia and Its Clinical Significance.
Article in Journal of immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Detection of Monocyte Subsets in the Bone Marrow of Patients With Acute Myeloid Leukemia and Its Clinical Significance.Journal of immunology research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The bone marrow (BM) microenvironment plays a crucial role in acute myeloid leukemia (AML), but the distribution and clinical significance of monocyte subsets within this compartment remain poorly characterized. This study aimed to investigate the composition of BM monocyte subpopulations and their relationship with systemic immunity and clinical outcomes in AML patients. Methods: We collected BM samples from 98 AML patients (including 23 newly diagnosed, 28 nonremission, and 47 complete remission [CR] cases) and 23 healthy controls (HCs). Using flow cytometry, we analyzed monocyte subsets (classical, intermediate, nonclassical) and monocytic myeloid-derived suppressor cells (m-MDSCs) in BM, along with T lymphocyte subsets in peripheral blood. Survival analysis was performed with 1-year follow-up data. Results: Both the proportion of intermediate monocytes and m-MDSCs among total monocytes were significantly elevated in newly diagnosed AML patients compared to those in HCs ( Conclusions: BM monocyte subsets, particularly intermediate monocytes, serve as significant indicators of disease progression and survival in AML. Their correlation with peripheral T-cell immunity suggests their potential role in modulating antileukemic immune responses. These findings highlight the prognostic value of BM monocyte profiling and provide insights for developing novel immunotherapeutic strategies in AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.